WP 2.24: A national longitudinal study of metastases-directed local ablative therapy for patients with oligometastatic disease - a combined interventional and observational trial (OLIGO-DK)

A national longitudinal study of metastases-directed local ablative therapy for patients with oligometastatic disease - a combined interventional and observational trial (OLIGO-DK)
Patients with few metastatic lesions (oligometastatic disease, OMD) may benefit from local ablative therapy to the metastatic sites. Often, patients with OMD are treated with different local therapies, in more metastatic sites, and at repeated times during their disease courses, complicating evaluation.
OLIGO-DK is a national, longitudinal cohort study with embedded trials. It will include patients across cancer diagnoses, metastatic sites, and local treatment modalities, and follow them prospectively while evaluating the longitudinal trajectories of these complex disease courses.
The primary endpoint is time to failure of the local ablative therapy strategy, secondary endpoints include progression-free survival, overall survival, time to change of systemic treatment, as well as prospective data on complications and toxicity after local treatments, and longitudinal quality of life data.
All prospective data will be collected by a centralized study unit through phone calls and electronic questionnaires, while the remaining follow-up with evaluation scans and blood tests will be managed by the local department according to clinical guidelines.
Within OLIGO-DK, trials can be embedded, such as translational studies, randomized trials with local treatments, or cancer-specific trials. These embedded trials can benefit from the infrastructure of the cohort, such as identification and recruitment of patients and centralized data collection.
OLIGO-DK aims to shed light on these complex disease trajectories for patients with oligometastatic disease and generate evidence to be utilized in national guidelines.

Awarded to: Gitte Persson (Herlev and Gentofte Hospital Hospital) – CFA2

Awarded grant to suport TAP personnel.